DRUG/DO

SE/ EVALUATI
CLASSIFICATI INDICATION/CO PRINCIPLE OF TREATMENT
FREQUEN ON/ NTRA CARE ON
CY INDICATION/SIDE
MOA
EFFECTS
DRUG/DO INDICATION/CONTR
SE/ A EVALUATIO
CLASSIFICATI PRINCIPLE TREATME
FREQUEN ON/ MOA INDICATION/SIDE OF CARE NT N
CY EFFECTS
Liothyronin Thyroid hormone I-Congenital hypothyroidism; 1.)Watch for angina, 1.)Teach patient
Myxedema; myxedema coronary occlusion, or importance of
e sodium
coma, premyxedema coma; stroke in patients w/ compliance. Tell him to
(T3) simple (nontoxic) goiter; arteriosclerosis who are take thyroid hormones at
Unclear. thyroid hormone receiving rapid same time each day,
(Cytomel) replacement replacement. preferably before
Enhances oxygen
breakfast, to maintain
consumption by C/I-Hypersensitive to drug 2.)Long term therapy constant hormone levels
most tissues of and in those w/ acute MI causes bone loss in & help prevent insomnia.
Tab 25 the body; uncomplicated by premenopausal &
mcg/day increases the
hypothyroidism, uncorrected postmenopausal 2.)make sure patient
adrenal insufficiency; use women. Consider a understands that
basal metabolic cautiously in elderly patients basal bone density replacement therapy is
rate and the & in those w/ angina measurement, & usually for life. Drug
metabolism of pectoris, hypertension, other monitor patient closely should never be stopped
CV disorders, renal for osteoporosis. unless directed by
carbohydrates,
insufficiency or ischemia; prescriber.
lipids and use cautiously w/ diabetes 3.)Thyroid hormone
proteins. insipidus, mellitus replacement 3.)Advise patient who
requirements are about has achieved a stable
S/E 25% lower in patients response not to change
older than age 60 than brands.
CNS-nervousness, insomnia, in young adults.
tremor, headache 4.)tell patient to report
4.)Monitor pulse and BP unusual bleeding and
CV-tachycardia, arrhythmias, bruising.
angina, cardiac 5.)When switching from
decompensation & collapse IV to PO therapy, 5.)For diabetic patients,
gradually increase IV advise them to monitor
GI-diarrhea & vomiting dose while starting PO glucose level closely.
dose.
Metabolic-weight loss 6.)Advise woman to
6.)In pregnant patients, report pregnancy to
Muscu-accelerated bode dosage may need to be prescriber because
maturation in infants & increased. dosage may need
children adjustments.

Skin-skin reactions,
diaphoresis

Other- heat intolerance

Salt of stable
Potassium
iodine
iodide I-To prepare for 1.)The FDA doesn’t
thyroidectomy; thyrotoxic recommend prophylaxis 1.)Show patient how to
(ThyroSafe) crisis; Radiation protectant w/ potassium iodide for mask salty taste of oral
 Inhibits thyroid for thyroid gland
hormone C/I-w/ tuberculosis, acute
65 mg/ml formation, limits bronchitis, iodide
iodine transport hypersensitive or
into the thyroid hyperkalemia; use
cautiously in patients w/
gland, & blocks
goiter or autoimmune
thyroid hormone thyroid disease.
release.
S/E
CNS-fever
EENT-periorbital edema
GI-nausea & vomiting,
diarrhea, inflammation of
salivary glands, burning
mouth and throat, sore teeth
and gums
Metabolic-potassium toxicity
Skin-acneiform rash
Other-hypersensitivity
reactions
DRUG/DO INDICATION/CONTR
SE/
a radiation emergency
in adults over 40 y.o
unless a large internal
radiation dose is
anticipated.
2.)For thyrotoxicosis,
first iodine dose is given
at least 1 hour after first
dose of propylthiouracil
and methimazole.
3.)Dilute oral solution in
water, milk or fruit juice
and give after meals to
prevent gastric
irritation, hydrate
patient & mask salty
taste.
4.)Give iodides through
straw to avoid tooth
discoloration.
5.)Earliest signs of
delayed hypersensitivity
reactions caused by
iodides are irritation and
swollen eyelids.
6.)Store in light-
resistant container.
solution. Tell him to take
all forms of drug after
meals.
2.)Warn patient that
sudden withdrawal may
precipitate thyroid crisis.
3,)Teach patient s/s of
potassium toxicity,
including confusion,
irregular heartbeat,
numbness, tingling, pain
or weakness of hands or
feet & tiredness.
4.)Tell patient to ask
prescriber about using
iodized salt & eating
shellfish. These foods
contain iodine & may
alter drug’s
effectiveness.
5.)Tell patient not
increase the amount of
potassium through diet.
6.)tell patient to stop
drug & notify prescriber
if epigastric pain, rash,
metallic taste, nausea or
vomiting occurs.
FREQUEN CLASSIFICATI A PRINCIPLE TREATME EVALU
CY ON/ MOA OF CARE NT ATION
INDICATION/SIDE
EFFECTS
Calcitonin – Calcium regulator I-Paget disease of bone 1.)Skin test is usually 1.)When drug is given for
(osteitis deformmans); done in patients w/ postmenopausal
salmon
Hypercalcemia; suspected drug osteoporosis, remind
(Fortical) postmenopausal sensitivity before patient to take adequate
Decreases osteoporosis therapy. calcium and vitamin D
supplements.
osteoclastic C/I-Hypersensitive to drug 2.)Systemic allergic
200 activity by reactions are possible 2.)Show home care
units/ml in inhibiting S/E because hormone is patient & family member
2-ml osteocytic protein. Keep how to give drug. Tell
CNS-headache, weakness, epinephrine nearby. them to do so at bedtime
ampoules osteolysis; dizziness, paresthesia if only one dose is
decreases mineral 3.)Give at bedtime, needed daily. If nasal
CV-chest pressure, facial
release and when possible, to spray is prescribed, tell
flushing minimize nausea and
matrix or collagen patient to alternate
vomiting. nostrils daily.
breakdown in EENT-eye pain, nasal
bone. congestion, rhinitis 4.)Use freshly 3.)Advise patient to
reconstituted solution notify prescriber if
GI-transient nausea, unusual
w/in 2 hours. significant nasal irritation
taste, diarrhea, anorexia,
vomiting, epigastric or evidence of an allergic
5.)Observe patient for response occurs.
discomfort, abdominal pain signs of hypocalcemic
tetany during therapy 4.)Inform patient that
GU-increased urinary
(muscle twitching, facial flushing and
frequency, nocturia
titanic spasms and warmth occur in 20% to
Resp-shortness of breath seizures when 30% of patients w/in
hypocalcemia is minutes of injection &
Skin-rash, pruritus of ear severe). usually last about 1 hour.
lobes
6.)Periodic examinations 5.)Tell patient that
Other-anaphylaxis, edema of of urine sediment are nausea and vomiting
feet, chills, tender palms and recommended. may occur at the onset
soles of therapy.
7.)In patients w/ good
first response to drug
who have relapse,
expect to evaluate
antibody response to
the hormone protein.
Calcitriol Vitamin D analog,
1.)Tell patient to
(1,25- Calcium regulator immediately report early
dihydoxych 1.)Monitor calcium level; symptoms of Vitamin D
olecalciferol this level times the intoxication.
I-Hypocalcemia in patients phosphate level
) undergoing long term shouldn’t exceed 70. 2.)Instruct patient to
(Rocaltrol) Stimulates dialysis; During dose adjustment, adhere to diet and
Hypoparathyroidism; To determine calcium level calcium supplementation
calcium
manage secondary twice weekly. If and to avoid unapproved
absorption from hyperparathyroidism and hypercalcemia occurs, OTC drugs and antacids
0.25 to the GI tract and resulting metabolic bone stop drug and notify that contain magnesium.
0.75 mcg promotes disease in predialysis prescriber, but resume
patients. after calcium level 3.)Tell patient that drug
PO daily movement of
returns to normal. is the most potent form
calcium from C/I-w/ hypercalcemia or of Vitamin D available
bone to blood. Vitamin D toxicity; use 2.)Monitor phosphorus and shouldn’t be taken
cautiously in patients level, esp. in by anyone else.
receiving cardiac glycosides hypoparathyroid
and in those w/ sarcoidosis patients and dialysis 4.)Encourage patient to
or hyperparathyroidism patients. receive adequate daily
intake of calcium.
S/E 3.)Reduce dose as
parathyroid hormone
CNS-headache, somnolence, levels decrease in
weakness, irritability response to therapy.

CV-hypertension, 4.)Protect drug from

arrhythmias heat and light.

EENT-conjunctivitis,
photophobia, rhinorrhea

GI-nausea and vomiting,

constipation, polydipsia,
pancreatitis, metallic taste,
dry mouth, anorexia

GU-polyuria, nocturia

Metabolic-weight loss

Muscu-bone and muscle pain

Skin-pruritus

Other-hyperthermia,
decreased libido

DRUG/DO INDICATION/CONTR
SE/ CLASSIFICATI A PRINCIPLE TREATME EVALU
ON/ MOA OF CARE NT ATION
FREQUEN INDICATION/SIDE
CY EFFECTS
 Glimepirid Antidiabetic, oral; I-Adjunct to diet and
exercise to lower glucose
e second
level in patients w/ type 2
generation diabetes whose
(Amaryl) sulfonylurea
hyperglycemia can’t be
managed by diet and
exercise alone
1-2 mg Lowers glucose C/I-Hypersensitivity; in
once a day level, possibly by pregnant women or elderly
patients and as sole therapy
stimulating
for type 1 diabetes; in
release of insulin breastfeeding women
from functioning because it can cause
pancreatic beat hypoglycemia in breast-fed
infants; use cautiously w/
cells, and may
allergic to sulfonamides.
lead to increased
sensitivity of S/E
peripheral tissues
CNS-dizziness, asthenia,
to insulin. headache
EENT-changes in
accommodation
GI-nausea
Hematologic-leukopenia,
hemolytic
anemia,agranulocytosis
Skin-pruritus, erythema,
urticaria
Sulfonylurea
Glipizide
(Glucotrol)
Unknown. A
sulfonylurea that
probably I-Adjunct to diet to lower
5mg PO glucose level in patients w/
stimulates insulin
daily type 2 (non-insulin-
release from
dependent) diabetes; To
pancreatic beat
1.)Glimepiride and 1.)Tell patient to take
insulin May be used drug with first meal of
together in patients who the day.
lose glucose control
2.)make sure patient
after first responding to
therapy. understands that
therapy relieves
2.)Monitor fasting symptoms but doesn’t
glucose level cure the disease. He
periodically to should also understand
determine therapeutic potential risks and
response. Also monitor advantages of taking
glycosylated drug and of other
hemoglobin level, treatment methods.
usually every 3-6
months, to precisely 3.)Advise patient to wear
or carry medical
assess long-term
glycemic control. identification at all times.
3.)Use of oral 4.)Advise woman to
hypoglycemic may carry consult prescriber before
planning pregnancy.
higher risk of CV
mortality than use of Insulin may be needed
diet alone or of diet and during pregnancy and
insulin therapy. breastfeeding.
4.)When changing 5.)Advise patient ot
patient from other consult prescriber before
taking any OTC products.
sulfonylureas to
glimepiride, a transition
6.)Advise patient to
period isn’t needed.
avoid alcohol w/c lowers
glucose level.
1.)Give immediate- 1.)Instruct patient about
release tablet about 30 disease and importance
minutes before meals. of following therapeutic
regimen, adhering to
2.)Some patients may diet, losing weight,
attain effective control getting exercise,
on a once-daily following personal
regimen, whereas other hygiene programs, and
respond better w/ avoiding infection.
 cells, reduces replace insulin therapy
glucose output by C/I-Hypersensitivity; in
the liver, and pregnancy or breastfeeding
increases women; use cautiously in
peripheral patients w/ renal or hepatic
disease
sensitivity to
insulin. S/E
CNS-dizziness, drowsiness,
headache, syncope
GI-nausea, dyspepsia,
flatulence, constipation,
diarrhea
Hematologic-leukopenia,
hemolytic anemia
Hepatic-cholestatic jaundice
Metabolic-hypoglycemia
Resp-rhinitis
Skin-rash, pruritus,
photosensitivity
DRUG/DO INDICATION/CONTR
SE/
divided dosing. Explain how and when to
monitor glucose level,
3.)Patient may switch and teach recognition of
from immediate-release episodes of low & high
dose to extended- glucose levels.
release tablets at the
nearest equivalent total 2.)tell patient to carry
daily dose. candy or other simple
sugars to treat mild low-
4.)During periods of glucose episodes.
increased stress, patient
may need insulin 3.)Instruct patient not to
therapy. Monitor patient change drug dosage
closely for w/out prescribers
hyperglycemia in these consent and to report
situations. abnormal blood or urine
glucose test results.
5.)Patient switching
from insulin therapy to 4.)Advise woman
an oral antidiabetic planning pregnancy to
should check glucose first consult prescriber.
level at least three Insulin may be needed
times a day before during pregnancy and
meals. Patient may breastfeeding.
need hospitalization
during transition. 5.) Advise patient to
avoid alcohol w/c lowers
glucose level.
FREQUEN CLASSIFICATI A PRINCIPLE TREATME EVALU
CY ON/ MOA OF CARE NT ATION
INDICATION/SIDE
EFFECTS
 Hydrocorti Glucocorticoid I-Severe inflammation, 1.)Determine whether 1.)Tell patient not to stop
adrenal insufficiency; Shock; patient is sensitive to drug abruptly or w/out
sone
adjunct treatment for other corticosteroids. prescriber’s consent.
ulcerative colitis and
(Cortenema 2.)For better results and 2.)Instruct patient to
Not clearly proctitis
) less toxicity, give a take oral form of drug w/
defined. C/I-Hypersensitivity; use once-daily dose in milk or food.
Decreases cautiously in patient w. morning.
inflammation, recent MI; w/ GI ulcer, renal 3.)Teach patient s/s early
240mg/day mainly by disease, hypertension, 3.)Give oral dose w/ adrenal insufficiency;
diabetes mellitus, food when possible. fatigue, muscle
stabilizing Patient may need other weakness, joint pain,
hypothyroidism, active
leukocyte hepatitis drug to prevent GI fever, anorexia, nausea,
lysosomal irritation. shortness of breath,
membranes; S/E dizziness and fainting.
3.)Enema may produce
suppresses CNS-euphoria, insomnia same systemic effects 4.)Warn patient about
immune psychotic behavior EENT- as other forms of easy bruising.
response; cataracts, glaucoma hydrocortisone. If
enema therapy must 5.)Advise patient
stimulates bone GI-nausea, increased receiving long term
exceed 21 days, taper
marrow, and appetite, peptic ulceration off by giving every other therapy to have periodic
influences night for 2 to 3 weeks. eye examinations.
Hematologic-easy bruising
protein, fat and
4.)Always adjust to 6.)Urge patient receiving
carbohydrate Skin-delayed wound healing long-term therapy to
lowest effective dose.
metabolism. consider exercise or
Muscu-qrowth suppression, 5.)Monitor patients physical therapy. Also,
muscle weakness weight, BP, and tell him to ask prescriber
electrolyte level. about Vitamin D or
calcium supplement.
6.)Watch for depression
or psychotic episodes,
esp. during high-dose
therapy.

Triamcinolo
ne 1.)Drug isn’t used for 1.)Instruct patient to
Glucocorticoid I-Severe infalammation, alternate-day therapy. take oral form of drug w/
milk or food.
(Aristospan immunosuppression; asthma
2.)Parenteral form isn’t
) for IV use. 2.)Teach patient s/s early
C/I-Hypersensitive; use
More potent cautiously w/ recent MI, GI adrenal insufficiency;
ulcer, renal disease, 3.)Monitor patients fatigue, muscle
than prednisone.
3 mg/ml Intermmediate- hypertension,DM,osteoporos
is
acting. Has no
mineralocorticoid S/E
activity.
CNS-euphoria, insomnia,
pseudotumor cerebri,
seizures
GI-pancreatitis, peptic
ulceration, GI irritation
GU-menstrual irregularities,
increased urine calcium level
Metabolic-hypokalemia,
hyperglycemia and
carbohydrate intolerance
Muscu-growth suppression
weight, BP and weakness, joint pain,
electrolyte level. fever, anorexia, nausea,
shortness of breath,
4.)Watch depression or dizziness and fainting.
psychotic episodes, esp.
high dose therapy. 3.)Tell patient not to stop
drug abruptly or w/out
5.)Diabetic patient may prescriber’s consent.
need increased insulin
dosage; monitor glucose 4.)Warn patient on long
level. term therapy about
cushingoid effects (moon
6.)Gradually reduce face, buffalo hump) and
dosage after long term the need to notify
therapy. Drug may prescriber about sudden
affect patient’s sleep. weight gain and swelling.
7.)Unless 5.)Tell patient to report
contraindicated, give slow healing.
low-sodium diet that’s
high in potassium and
protein. Give potassium
supplements as needed.